Balomenib Phase Ib: Durable Glycemic Signal Without a Mechanism — Promise Constrained by Opacity

Clywedog's Balomenib Shows Sustained Glycaemic Control in Phase Ib

Clywedog Therapeutics announced final results from its Phase Ib trial of investigational oral drug balomenib in 60 adults with type 2 diabetes (T2D). The placebo-controlled, double-blind, randomised study showed sustained reductions in haemoglobin A1c (HbA1c) and fasting plasma glucose (FPG) even after treatment ended. At week 12, the placebo-adjusted mean reduction in HbA1c was 0.77%, and FPG was 1.29mmol/L (23mg/dL). The drug demonstrated a favorable safety and tolerability profile, with no unexpected drug-related adverse events or treatment discontinuations. Clywedog plans to initiate a Phase IIa study in Q4 2026.

• Balomenib demonstrated sustained improvements in glycaemic control, with placebo-adjusted mean reductions of 0.77% in HbA1c and 1.29mmol/L (23mg/dL) in fasting plasma glucose at week 12, three months after the final dose. These effects were consistent with a disease-modifying mechanism of action.
• The trial's primary endpoint of tolerability and safety at week 4 was met, with no unexpected drug-related adverse events, serious adverse events, or treatment-related discontinuations observed. The drug was well-tolerated throughout the 16-week observation period.
• Exploratory endpoints, including an oral glucose tolerance test at day 85, showed significant placebo-adjusted reductions in total glucose area under the curve, peak glucose, and two-hour glucose. Clywedog Therapeutics attributes these improvements to menin signalling inhibition, enhancing both insulin sensitivity and secretion, and plans a Phase IIa study in Q4 2026.

Balomenib's Promising Phase Ib Safety and Sustained Efficacy in T2D

The SURPASS-2 trial, a randomised Phase 3 study enrolling 1,879 adults with type 2 diabetes, evaluated tirzepatide (5, 10, and 15 mg) against semaglutide (1 mg) across 40 weeks. A post hoc analysis of this trial demonstrated that all doses of tirzepatide increased attainment of both standard and intensive therapeutic targets — encompassing HbA1c, blood pressure, LDL-cholesterol, and body weight — compared with semaglutide. For standard targets, 34% of semaglutide-treated participants met three or more goals, versus 42%, 53%, and 57% with tirzepatide 5, 10, and 15 mg, respectively. For intensive targets, the corresponding figures were 8% with semaglutide versus 15%, 20%, and 29% with tirzepatide. Tirzepatide increased the odds of achieving HbA1c below 53 mmol/mol (OR 1.50 [95% CI 1.12, 2.00]), HbA1c below 48 mmol/mol (OR 1.88 [95% CI 1.49, 2.36]), weight loss greater than 10% (OR 2.72 [95% CI 2.14, 3.47]), weight loss greater than 15% (OR 3.86 [95% CI 2.69, 5.55]), and the intensive blood pressure target (OR 1.45 [95% CI 1.17, 1.81]).

A 5-year simulation study using the BRAVO diabetes model, extrapolating from the SURPASS-2 and SUSTAIN-4 trials, projected the long-term complication burden associated with tirzepatide, semaglutide (1 mg), and insulin glargine. Under an optimistic scenario — in which 1-year treatment effects persisted — tirzepatide 15 mg was associated with a projected 5-year risk reduction in cardiovascular adverse events (rate ratio 0.64, 95% CI 0.61–0.67) and microvascular composite events (rate ratio 0.67, 95% CI 0.64–0.70) versus insulin glargine. Semaglutide similarly projected reductions in cardiovascular adverse events (rate ratio 0.75, 95% CI 0.72–0.79) and microvascular composite (rate ratio 0.79, 95% CI 0.76–0.82) versus insulin glargine. The 5-year risk reduction in diabetes-related complication events and mortality for tirzepatide 15 mg versus insulin glargine ranged from 49% to 10% under the optimistic scenario, reduced by 17%–33% under a conservative scenario. The authors noted that the long-term cardiovascular benefit of tirzepatide requires further validation in a prospective clinical trial.

In the real-world setting, a retrospective observational cohort study conducted in the United Arab Emirates evaluated once-weekly subcutaneous semaglutide in 278 adults with type 2 diabetes over 12 months. Adjusted HbA1c decreased by -0.89% (95% CI -1.07 to -0.70) at 6 months and -0.71% (95% CI -0.91 to -0.50) at 12 months (both p < 0.001). Body weight decreased by -3.09 kg at 6 months and -4.77 kg at 12 months (p < 0.001), and systolic blood pressure decreased by -3.56 mmHg (95% CI -6.17 to -0.96; p = 0.007) at 6 months. At 12 months, 39% of patients achieved an HbA1c reduction of ≥1%, 43% achieved ≥5% weight loss, and 23% achieved the composite endpoint. Higher baseline HbA1c was identified as a predictor of glycemic response (OR 1.85; 95% CI 1.26 to 2.88).

Menin Signaling: An Emerging Target for Type 2 Diabetes

Several G protein-coupled receptors (GPCRs) expressed in pancreatic beta cells have emerged as compelling therapeutic targets in type 2 diabetes. GPR40, activated by medium- and long-chain fatty acids, amplifies glucose-stimulated insulin secretion (GSIS) through the GPR40-PLC/PKC-TRPC3 channel pathway, which depolarizes the plasma membrane of beta cells. GPR40 agonists such as fasiglifam have demonstrated potentiation of GSIS at 8.3 and 16.7 mM glucose, positioning this receptor class as a promising avenue for insulin secretagogue development. Alongside GPR40, the incretin receptors GLP-1R and GIPR — whose expression in INS-1 beta cells is upregulated by metformin and AICAR, both activators of 5-AMP-activated protein kinase (AMPK) — represent additional GPCR-based targets with established and evolving therapeutic relevance.

Gluconeogenesis inhibition represents a mechanistically distinct strategy. Fructose-1,6-bisphosphatase (FBPase), a rate-controlling enzyme of gluconeogenesis, has been identified as a target for reducing excessive endogenous glucose production (EGP), a key driver of hyperglycemia in type 2 diabetes. Potent and selective inhibitors targeting the allosteric site of FBPase were developed using adenosine monophosphate (AMP) as a structural starting point, with oral delivery enabled through a diamide prodrug class. The lead compound CS-917 reduced gluconeogenesis and EGP in diabetic rodents, ameliorating both fasting and postprandial hyperglycemia without weight gain, hypoglycemia, or major perturbation of lactate or lipid homeostasis. Clinical evaluation of CS-917 demonstrated a favorable safety profile and clinically meaningful reductions in fasting glucose in patients with type 2 diabetes, with a second-generation inhibitor, MB07803, under further investigation.

At the intersection of metabolic and inflammatory pathways, the NLRP3 inflammasome has gained attention as a therapeutic target. Oligomers of human islet amyloid polypeptide (IAPP), co-secreted with insulin, trigger NLRP3 inflammasome activation in macrophages, driving IL-1β production and islet pathology. The human serum protein C4b-binding protein (C4BP) inhibits IAPP-mediated inflammasome activation by preventing loss of macrophage phagolysosomal integrity, preserving beta cell function and viability in an IL-1β-dependent manner. Separately, intermittent fasting therapy has been shown to inhibit NLRP3 inflammasome activation in a rat insulin resistance model, reducing IL-1β, IL-18, and caspase-1 levels while increasing expression of IRS1, IRS2, and GLUT1. Additionally, in the context of metabolic dysfunction-associated steatotic liver disease — a condition sharing risk factors with type 2 diabetes — activators of nuclear factor erythroid 2-related factor 2 (Nrf2), including a trans-resveratrol and hesperetin combination, have been shown to divert excess glucose metabolism to the pentose phosphate pathway, decreasing ChREBP and hexosamine pathway activation and reducing lipogenic gene expression, representing a novel strategy for addressing glycolytic overload and insulin resistance.

Why Sustained Glycaemic Control Matters in T2D Treatment

Long-term glycaemic control in type 2 diabetes (T2DM) extends well beyond HbA1c reduction, with sustained treatment effects on cardiovascular, renal, and metabolic outcomes now central to therapeutic evaluation. Data from randomised controlled trials demonstrate that more intensive glucose control produces a modest 9% reduction in major cardiovascular events (MACE), alongside a 20% reduction in kidney events and a 13% reduction in eye events. Cardiovascular outcomes trial (CVOT) programmes, initiated following FDA guidance issued in 2008, have further stratified the long-term benefit profiles of individual drug classes. Notably, DPP-4 inhibitors — including saxagliptin, alogliptin, and sitagliptin — and the GLP-1 receptor agonist lixisenatide produced no significant difference in MACE versus placebo or usual care, whereas empagliflozin, canagliflozin, liraglutide, and semaglutide demonstrated cardiovascular benefit. The combination of intensive glycaemic control with these newer agents may decrease the incidence of MACE, nephropathy, and retinopathy, with reductions in cardiovascular mortality and heart failure also observed depending on the agent used.

Durability of response is a recognised challenge in T2DM pharmacotherapy, particularly with older second-line agents. Sulfonylureas, commonly used after metformin failure, are associated with poor durability, hypoglycaemia, and weight gain. In contrast, a 4-year (208-week) Phase III trial comparing empagliflozin 25 mg once daily with glimepiride as add-on to metformin — the largest study of its kind at the time — was designed specifically to evaluate long-term glycaemic control, beta-cell function, cardiovascular risk factors, and markers of renal function. Baseline characteristics of the 1,545 treated patients included a mean HbA1c of 7.92% and mean BMI of 30.11 kg/m², with the study's primary endpoint being change from baseline in HbA1c and secondary endpoints encompassing body weight, confirmed hypoglycaemia incidence, and blood pressure changes. SGLT-2 inhibitors as a class have demonstrated reductions in hyperglycaemia, body weight, and blood pressure with a low incidence of hypoglycaemia in Phase II/III trials, supporting their durability profile relative to sulfonylureas.

Renal outcomes represent a critical dimension of long-term treatment durability in T2DM. In the EMPA-REG OUTCOME trial, empagliflozin improved clinically relevant kidney outcomes by 39%, slowed progression of chronic kidney disease, and reduced albuminuria in patients with type 2 diabetes and established cardiovascular disease. In the Asian subgroup of that trial (1,517 of 7,020 treated patients), empagliflozin reduced the risk of incident or worsening nephropathy (hazard ratio 0.64, 95% confidence interval 0.49–0.83), progression to macroalbuminuria (hazard ratio 0.64, 95% confidence interval 0.49–0.85), and the composite of doubling of serum creatinine, initiation of renal-replacement therapy, or renal death (hazard ratio 0.48, 95% confidence interval 0.25–0.92), with effects consistent with the overall trial population. For GLP-1 receptor agonists, a meta-analysis of 43 randomised trials enrolling 63,134 patients with T2DM confirmed a significant reduction in MACE (MH-OR 0.87 [0.83, 0.92]) and all-cause mortality (MH-OR 0.89 [0.83, 0.96]), with a non-statistical trend toward reduction in heart failure (MH-OR 0.93 [0.85, 1.01]) and no increase in atrial fibrillation risk (MH-OR 0.94 [0.84, 1.04]), underscoring the breadth of long-term benefit achievable with contemporary T2DM therapies.